Loading
Life sciences · Journal article
Clinical Nuclear Medicine · September 23, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
We report a 55-year-old man with metastatic castration-resistant prostate cancer who developed a dramatic "scintigraphic flip" after the second cycle of ¹⁷⁷Lu-PSMA therapy. Post-therapy SPECT and follow-up ¹⁸F-PSMA PET/CT showed increased diffuse marrow uptake with paradoxically reduced salivary-gland and liver activity. Despite improved bone pain, reduced analgesic use, and no clinical or laboratory warning signs, this silent redistribution preceded grade III thrombocytopenia and marked anemia, hospitalization for transfusion and supportive care, and death. This case suggests that interval PSMA PET/CT, particularly in selected high-risk patients, may help identify occult marrow redistribution and support individualized dose adaptation.